Clotting Factor Home Care

PHS refers to Section 340B of the Public Health Service Act of the Veteran's Health Care Act which was enacted in 1992. The PHS Act covers a diverse group of healthcare organizations including community health centers, black lung clinics, AIDS clinics, and hemophilia treatment centers.

Hemophilia treatment centers (HTCs) receive federal grant money from the Maternal and Child Health Bureau (MCHB) of the Department for Health and Human Services. As such, they are considered a "covered entity" under the PHS Act.

Hemophilia treatment centers are eligible to purchase certain clotting factor products at a discounted rate as determined by the federal government and by PHS guidelines.

Under the PHS Act, hemophilia treatment centers may purchase clotting factor products from manufacturers and distribute to patients of the center. The revenue derived from the sale of these products goes directly to support the center’s clinical programs and to provide much-needed services, such as additional nursing, social services, physical therapy, screening programs, and training programs for new hematologists.

Although hemophilia treatment centers may receive some funding from the Maternal Child Health Bureau, the dollar amount falls far short of what is needed to keep an HTC functional. In addition, these federal dollars are fewer and fewer each year. The reason many HTCs develop their own PHS program is to have the ability to maintain and grow services that they can provide to their patients without relying on funds from the federal government.

• Lower-cost clotting factor products will extend a patient’s lifetime limit on their insurance.
• Using the UC San Diego Home Infusion Pharmacy for your factor product allows for a streamlined internal process to meet your needs.
• Joining our Total Hemophilia Care program directly contributes to the financial health, vitality and longevity of the HTTC.